重组Anti-IRS1 (phospho Y632)抗体[EPR259(2)]
Anti-IRS1 (phospho Y632) antibody [EPR259(2)]
- RabMAb
- Recombinant
- 了解详情
Be the first to review this product! Submit a review
|
(11 Publications)
Rabbit Recombinant Monoclonal IRS1 phospho Y632 antibody. Suitable for WB and reacts with Human samples. Cited in 11 publications.
查看别名
Insulin receptor substrate 1, IRS-1, IRS1
- WB
Unknown
Western blot - Anti-IRS1 (phospho Y632) antibody [EPR259(2)] (AB109543)
All lanes:
Western blot - Anti-IRS1 (phospho Y632) antibody [EPR259(2)] (ab109543) at 1/1000 dilution
Lane 1:
293T cell lysate, untreated at 10 µg
Lane 2:
293T cell lysate treated with Alkaline Phosphatase at 10 µg
Secondary
All lanes:
HRP-labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 131 kDa
false
- WB
CiteAb
Western blot - Anti-IRS1 (phospho Y632) antibody [EPR259(2)] (AB109543)
IRS1 (phospho Y632) western blot using anti-IRS1 (phospho Y632) antibody [EPR259(2)] ab109543. Publication image and figure legend from Song, Q., Sun, X., et al., 2017, Oncotarget, PubMed 28002807.
ab109543 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab109543 please see the product overview.
The RTK/IRS1-mediated reactivation of AKT was responsible for the insufficient inhibition of the cell growth by the AKTi(A) HCT-116 cells were pretreated with AKTi for 46 hr, and then treated with AKTi or RTKis (LOJ) for 2 hr. The whole cell lysates were processed for western blot and probed with indicated antibodies. Relative AKT phosphorylation levels were quantified to DMSO treatment, and illustrated as numbers below the blots. (B) SW1116 cells were treated with AKTi at various concentrations for 1 hr and 24 hr. The whole cell lysates were processed for western blot and probed with indicated antibodies. (C) Phospho-RTK arrays of SW1116 cells, which were treated with DMSO (NC) or MEKi for 24 hr. Positive dots were numbered and illustrated below the arrays. (D) SW1116 cells which were pretreated with 0.25 μM AKTi for 24 hr and then treated with 10 μM LY294002 (PI3Ki), 2.5 μM GSK2334470 (PDKi), or 1 μM triciribine (PIP3-AKT binding inhibitor) for 1 hr. The whole cell lysates were processed for western blot and probed with indicated antibodies. (E) LS174T, LOVO and HCT-116 cells were treated with single RTKi or the specific RTKis with or without AKTi for 24 hr. The whole cell lysates were processed for western blot and probed with indicated antibodies. IRS1 phosphorylation (Tyr895) was quantified and normalized to DMSO treatment (bottom panel). The drug concentrations were as follows : AKTi : 0.25 μM; LAP (L) : 0.5 μM; OSI (O) : 0.5 μM; JNJ (J) : 0.05 μM.
false
不同偶联物与剂型 (1)
-
Anti-IRS1 (phospho Y632) antibody [EPR259(2)] - BSA and Azide free
反应性数据
产品详情
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
性能和储存信息
形式
纯化工艺
存储溶液
运输条件
推荐的短期储存条件
推荐的长期储存条件
储存信息
补充信息
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
IRS1 helps mediate the effects of insulin by acting as a downstream effector in the insulin signaling cascade. IRS1 functions in a complex manner binding with PI3K (phosphoinositide 3-kinase) after phosphorylation at specific tyrosine residues. This interaction is important for further signaling events leading to the regulation of glucose uptake lipid synthesis and gene expression. Besides its role in energy balance IRS1 plays a significant part in cell growth and differentiation driven by its ability to relay signals from the insulin and IGF receptors.
Pathways
IRS1 is heavily involved in the insulin signaling pathway and the PI3K-Akt pathway. Upon phosphorylation IRS1 binds to proteins such as the PI3K initiating a cascade that ultimately activates Akt resulting in anabolic processes within cells. The pathway is essential for regulating basic functions like metabolism growth and survival. IRS1's interaction with other related proteins like IR (insulin receptor) and IGFR (insulin-like growth factor receptor) highlights its integrative role in cellular processes related to energy and growth.
产品实验方案
- Visit the General protocols
- Visit the Troubleshooting
靶点信息
文献 (11)
Recent publications for all applications. Explore the full list and refine your search
Endocrine connections 14: PubMed40742333
2025
Applications
Unspecified application
Species
Unspecified reactive species
Molecular carcinogenesis 64:552-564 PubMed39763297
2025
Applications
Unspecified application
Species
Unspecified reactive species
Endokrynologia Polska 75:61-70 PubMed38497391
2024
Applications
Unspecified application
Species
Unspecified reactive species
Aging 15:10291-10306 PubMed37812195
2023
Applications
Unspecified application
Species
Unspecified reactive species
Current issues in molecular biology 45:2296-2308 PubMed36975518
2023
Applications
Unspecified application
Species
Unspecified reactive species
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 55:e11741 PubMed35976267
2022
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 23: PubMed35806430
2022
Applications
Unspecified application
Species
Unspecified reactive species
Clinical and experimental pharmacology & physiology 46:1101-1110 PubMed31397492
2019
Applications
Unspecified application
Species
Unspecified reactive species
General and comparative endocrinology 281:105-116 PubMed31121164
2019
Applications
Unspecified application
Species
Unspecified reactive species
Molecular medicine reports 17:2169-2176 PubMed29207074
2017
Applications
Unspecified application
Species
Unspecified reactive species
Abcam Product Promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com